October Products

KACTUS has developed the following new products to facilitate the latest innovations in drug development. Select a product category to jump to a specific section. Alternatively, click here to view all new products. 

KACTUS now offers glypican-3 (GPC3) protein and the G protein-coupled receptor GPRC5D as VLPs. GPC3 is a potential antibody therapeutic target for liver and other cancers. GPRC5D was thought to be expressed only in hair follicles but recently has shown potential as a CAR-T therapy target for myeloma. View our entire collection of VLPs here.

Cadherins

Cadherins play an important role in tissue homeostasis, as they are responsible for cell-cell adhesion during embryogenesis, tissue morphogenesis, differentiation and carcinogenesis. KACTUS has added new cadherin proteins including CDH-1, CDH-6, CDH-17, and CDH-19. These play a role in epithelial cell junctions, prostate cancer tumor growth, and Schwann cell development. View our entire collection of cadherins here. 

KACTUS has developed new proteins for drug discovery including MICA alpha 3 protein which plays a role in tumor evasion and Notch 3 protein which forms a transcriptional activator complex upon ligand binding. Additionally, KACTUS has developed a recombinant form of the adipocyte-derived hormone adiponectin and the hepatokine angiopoietin-like 3 protein, both of which play a role in lipid and glucose metabolism. View the full line new drug discovery targets below. 

SARS-COV-2 & Monkeypox

KACTUS continues to contribute to COVID-19 therapeutics with the release of two variations of SARS-COV-2 3C-like proteases. Additionally, with the new Monkeypox outbreak beginning in May 2022, KACTUS has developed two monkeypox virus proteins to assist drug discovery and development.

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is part of the RAS/MAPK pathway and plays a role in cell division, differentiation, and apoptosis. It is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. 

Interleukins

Interleukin-8 (IL-8) is a promising target for central nervous system disorders like glioma. IL-27 modulates inflammation with innate and adaptive immune cells. These are only a selection of IL products offered by KACTUS. View all of our interleukin proteins here.  

Other Products